AI in clinical operations: what a small biotech can use
There is a line running through clinical operations, and everything about whether a general AI system is useful or dangerous depends on which side of it you are standing. On one side is the trial record. On the other is the coordination around the trial. Only the second side is available here.
The line, before the pitch. The system described on this site is not a validated system. It produces no controlled record, nothing it writes is source data, and it has no place in anything that would be inspected. It is not a clinical trial management application, not an electronic data capture system, and not a trial master file. It does not touch patient data, and that is a scoping decision made in advance rather than a setting to be configured carefully.
What is left is the part of clinical operations that runs on email, and at a small company that is most of the week. A biotech with two people in clinical operations and one trial running through a contract research organization does not fail because its data capture is weak. It fails to keep up because one person is holding forty open threads with a vendor, three sites, a central lab and a monitoring group, and there is no place where the current state of all of that is written down.
What sits on each side
| The regulated side, not this | The coordination side, this |
|---|---|
| Source data, case report forms, the trial master file | The email thread where a deliverable date moved, and what moved with it |
| Safety reporting and any patient identifiable information | Your own commitments to the vendor, and theirs to you |
| Validated document control and audit trails | What the last oversight meeting decided, and why |
| Anything that goes into a submission | Contract notice windows, change orders, invoice triggers |
The right column has no owner at a company this size. It falls to whoever is closest, usually the same person who is also doing the left column properly, and it is the first thing to slip when a study gets difficult.
What that looks like in a week
A study manager writes at nine at night to say the interim data transfer moves by two weeks and, in the same paragraph, mentions that a change order will follow for the extra monitoring visits. Two facts, one email, and both of them affect something. A system built for this files the message against the study, changes the transfer date on the record, notes that the analysis window and the internal review now sit differently, opens an item for the change order that has not arrived yet, and drafts the reply for you to approve or bin. Nothing is sent without you.
It holds the promise made on the weekly call that never made it into minutes, and brings it back when it comes due. It watches your sent mail, so what you committed to is tracked the same way. It answers "what did we agree about that" from your own correspondence, with the source. It flags the contract notice window before it closes rather than the week after. That is the same machinery described on the program management page, pointed at a study rather than a program.
If there is patient data anywhere near the work you had in mind, stop here. The honest answer is that side is out of scope, not that it will be fenced carefully. A solo built system is not the right place to carry that risk, and an offer that pretended otherwise would be worth less than the paper it came on.
What to buy instead, where something else is right
If your gap is the trial record itself, buy a system built for it, and the honest comparison is on the clinical trial management software page. If your gap is oversight of the vendor running the study, that is its own category with its own literature, and it starts at build or buy on CRO oversight, which covers the plan, the meeting cadence and the software question together.
If your gap is that nobody can say on a Tuesday what the current answer is to a question the vendor asked three weeks ago, that is the one this addresses, and it is worth being clear that this is a smaller claim than the category usually makes.
One more constraint
It is single seat. One install, one person, one mail identity. A colleague's commitment is captured as your follow-up, never as a task assigned to them, and it will not message your CRO, your sites or your monitors. For an organization that needs several people looking at one shared study status, this is the wrong shape and something built for teams is the right one.
The adjacent regulated function, treated with the same boundary, is AI tools for regulatory affairs at a small biotech, and the rest of the function pages sit under AI for life sciences.
Only the right-hand column, and all of it
That nine at night note about the transfer slipping is filed against the study, the new date carried into what depended on it, the change order it mentions left open until it lands, and the reply drafted for you to approve. Source data and the trial master file stay untouched. Watch the demo.
See the demo